Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1052W HIGH $2.68
Volume
1.91 M
Value Traded
6.56 M
Short % Float
11.79%
-9.09%Week
-20.4%1 Month
-28.57%3 Month
-13.04%6 Month
-50.46%5 Year
-98.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
711.93 M
EPS (TTM)
-0.14
P/E Ratio
-
Ent. Value
572.76 M
Total Shares
444.87 M
Float Shares
218.98 M
Insiders
50.79%
Institutions
34.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LXRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Lexicon Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lexicon Pharmaceuticals, Inc.
227Total events
5Upcoming
58Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
●PublicationSotagliflozinApprovedPresentation
Post hoc SOLOIST-WHF analysis published in JACC: Heart Failure
recent worsening heart failuresource ↗
▲Milestone PaymentLX9851Corporate
Third $10 million milestone payment earned from Novo Nordisk
obesity and associated metabolic disorderssource ↗
▲First Patient DosedLX9851Trial
Key patient dosing milestone achieved in Phase 1 program
obesity and associated metabolic disorderssource ↗
▲Enrollment CompleteSotagliflozinApprovedTrial
Enrollment completed in Phase 3 SONATA-HCM study
hypertrophic cardiomyopathysource ↗
▲Other Regulator MilestoneSotagliflozinApprovedEx-US Regulatory
Viatris obtained regulatory approvals in UAE and Bahrain
heart failuresource ↗
●Poster PresentationSotagliflozinApprovedPresentation
Post hoc SOLOIST-WHF analysis presented at ESC Congress 2026
recent worsening heart failuresource ↗
●PublicationSotagliflozinApprovedPresentation
Post hoc SOLOIST-WHF analysis published in JACC: Heart Failure
recent worsening heart failuresource ↗
▲Enrollment CompleteSotagliflozinApprovedTrial
Completed enrollment in SONATA-HCM
hypertrophic cardiomyopathysource ↗
◆Oral PresentationPresentation
Lexicon Pharmaceuticals to present at 2026 Jefferies Global Healthcare Conference
◆Enrollment CompleteSotagliflozinApprovedTrial
SONATA-HCM enrollment completion expected mid-2026
Hypertrophic Cardiomyopathysource ↗
●Debt Royalty FinancingCorporate
Entered into $100 million loan facility with Hercules Capital
◆Oral PresentationpilavapadinPresentation
Oral presentation of additional efficacy data from PROGRESS Phase 2b study supporting pilavapadin 10 mg for Phase 3
diabetic peripheral neuropathic painsource ↗
●Poster PresentationpilavapadinPresentation
Poster presentation of preclinical evidence supporting pilavapadin as a novel oral therapy for spasticity
spasticity (multiple sclerosis, spinal cord injury)source ↗
◆Oral PresentationSotagliflozinApprovedPresentation
Sotagliflozin Improves Symptoms and Functional Capacity in Non Diabetic Patients with HFpEF: Results From the SOTA-P-CARDIA Trial
heart failure with preserved ejection fraction (HFpEF)source ↗
◆Poster PresentationSotagliflozinApprovedPresentation
Efficacy of Sotagliflozin for Heart Failure and Major Adverse Cardiovascular Events by Body Mass Index: A Prespecified Analysis of SCORED
type 2 diabetes, chronic kidney disease, cardiovascular risk factorssource ↗
▲Milestone PaymentLX9851Corporate
Second $10 million milestone payment earned from Novo Nordisk
obesitysource ↗
▲Enrollment UpdateSotagliflozinApprovedTrial
SONATA-HCM enrollment surpassed 50%
Hypertrophic Cardiomyopathysource ↗
●Trial InitiationLX9851Trial
Phase 1 development program initiated by Novo Nordisk
obesity and associated metabolic disorderssource ↗
▼Equity OfferingCorporate
Closing of approximately $94.6 million public offering and concurrent private placement
▲Milestone PaymentLX9851Corporate
$10 million milestone payment received from Novo Nordisk for LX9851
Obesity and Associated Cardiometabolic Disorderssource ↗
▼Equity OfferingCorporate
Pricing of approximately $94.6 million public offering and concurrent private placement
▲End Of Phase 2 MeetingpilavapadinFDA Meeting
Successful End-of-Phase 2 Meeting with FDA for pilavapadin in DPNP
diabetic peripheral neuropathic painsource ↗
▲Preclinical PoCLX9851Preclinical
Preclinical data published in Journal of the Endocrine Society validating ACSL5 as target for obesity
obesity and chronic weight managementsource ↗
▲Oral PresentationSotagliflozinApprovedPresentation
Sotagliflozin clinical data in HFpEF without diabetes presented at AHA 2025
heart failure with preserved ejection fraction (HFpEF) without diabetessource ↗
◆Oral PresentationSotagliflozinApprovedPresentation
Data from three studies of sotagliflozin presented at AHA Scientific Sessions 2025 and HCMS Scientific Sessions
heart failure, diabetes, chronic kidney disease, hypertrophic cardiomyopathysource ↗
▲IND Enabling CompleteLX9851Preclinical
All IND-enabling studies of LX9851 completed and submitted to licensee Novo Nordisk
Obesity and Associated Cardiometabolic Disorderssource ↗
▲Trial InitiationSotagliflozinApprovedTrial
Site initiation for SONATA-HCM Phase 3 study completed
Hypertrophic Cardiomyopathy (HCM)source ↗
●Timing GuidanceZynquistaPresentation
Additional data in support of potential resubmission of Zynquista for T1D submitted to FDA
Type 1 Diabetes (T1D)source ↗
▲End Of Phase 2 MeetingpilavapadinFDA Meeting
End-of-Phase 2 meeting request accepted by U.S. FDA
diabetic peripheral neuropathic painsource ↗
●Oral PresentationpilavapadinPresentation
Presented additional clinical data and program updates at 19th Annual Pain Therapeutics Summit
diabetic peripheral neuropathic painsource ↗
◆Poster PresentationpilavapadinPresentation
Poster: Results from Phase 2b PROGRESS Trial of Pilavapadin at Arrowhead Pain Summit
diabetic peripheral neuropathic painsource ↗
◆FDA Feedback ReceivedZynquistaFDA Meeting
FDA feedback from Type D meeting expected in Q4 2025
type 1 diabetessource ↗
▲End Of Phase 2 MeetingpilavapadinFDA Meeting
Successful End-of-Phase 2 meeting with FDA for pilavapadin
Diabetic Peripheral Neuropathic Painsource ↗
▲Oral PresentationpilavapadinPresentation
Presentation of Phase 2b PROGRESS data at EASD and NEUROdiab Annual Meetings
diabetic peripheral neuropathic painsource ↗
●Type D MeetingZynquistaFDA Meeting
Type D meeting with FDA held in September 2025
type 1 diabetessource ↗
◆Topline ReadoutLX9211Clinical Data
Topline data anticipated Q2 2025
Diabetic Peripheral Neuropathic Painsource ↗
▲Partnership / LicenseLX9851Corporate
Exclusive worldwide licensing agreement with Novo Nordisk for LX9851
obesity and chronic weight managementsource ↗
▲Topline ReadoutpilavapadinClinical Data
Topline results from Phase 2b PROGRESS study of pilavapadin in DPNP
diabetic peripheral neuropathic painsource ↗
◆End Of Phase 2 MeetingpilavapadinFDA Meeting
FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end
Diabetic Peripheral Neuropathic Pain (DPNP)source ↗
▲Partnership / LicenseLX9851Corporate
Licensing agreement with Novo Nordisk for LX9851
Obesity and Associated Cardiometabolic Disorderssource ↗
▲Other Regulator MilestoneSotagliflozinApprovedEx-US Regulatory
First commercial product shipped to United Arab Emirates (approval outside U.S.)
All indicationssource ↗
▲IND Enabling CompleteLX9851Preclinical
All IND-enabling activities completed for LX9851
Obesity and Associated Cardiometabolic Disorderssource ↗
▼Complete Response LetterZynquistaFDA Decision
FDA issued complete response letter for Zynquista NDA citing diabetic ketoacidosis risk
type 1 diabetessource ↗
▲Partnership / LicenseSotagliflozinApprovedCorporate
Exclusive licensing agreement with Viatris for sotagliflozin in all markets outside U.S. and Europe
heart failure, type 2 diabetes mellitus, chronic kidney diseasesource ↗
◆Timing GuidanceSotagliflozinApprovedPresentation
Preparing to resubmit NDA for sotagliflozin in T1D with CKD
Type 1 Diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How LXRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-28 | Sotagliflozin | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 23%
Micro Cap(rank 152 of 656)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| INPEFA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sotagliflozin Small moleculeNCT06481891 | Obstructive Cardiomyopathy, Hypertrophic | Phase 3 | ACTIVE NOT_RECRUITING | 500 | Feb 1, 2027 | ||||||
| LX9211 Small moleculeCompletedNCT04662281 | Postherpetic Neuralgia | Phase 2 | COMPLETED | 79 | Dec 28, 2022 | ||||||
| LX9211 Small moleculeCompletedNCT06203002 | Diabetic Peripheral Neuropathic Pain | Phase 2 | COMPLETED | 496 | Feb 24, 2025 | ||||||
| LX9211 Small moleculeCompletedNCT04455633 | Diabetic Peripheral Neuropathy | Phase 2 | COMPLETED | 319 | Jun 28, 2022 | ||||||
| Sotagliflozin Small moleculeMarketedNCT02926950 | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 4,783 | Mar 22, 2019 | ||||||
| Sotagliflozin Small moleculeMarketedNCT02383940 | Type 1 Diabetes Mellitus | Phase 3 | COMPLETED | 3,244 | Sep 1, 2016 | ||||||
| Telotristat etiprate Small moleculeMarketedNCT00853047 | Carcinoid Syndrome | Phase 3 | COMPLETED | 373 | Jun 1, 2014 | ||||||
| LX4211 Small moleculeMarketedNCT01292993 | Type 2 Diabetes Mellitus | Phase 2 | COMPLETED | 417 | - | ||||||
| Telotristat ethyl Small moleculeMarketedNCT03910387 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 2 | COMPLETED | 23 | Jun 29, 2022 | ||||||
| Telotristat ethyl Small moleculeMarketedNCT03423446 | Hepatic Impairment | Phase 1 | COMPLETED | 16 | Jun 15, 2018 | ||||||
| LX1606 Small moleculeMarketedNCT01932528 | Carcinoid Syndrome | Phase 1 | COMPLETED | 8 | - |
Clinical Trial Results
Readouts, endpoints and source filings for every LXRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pilavapadin | diabetic peripheral neuropathic pain (DPNP) | Phase 2b | 2026-04-17 | nominally significant reduction in Average Pain at Week 8 versus placebo; completion rates comparable to placebo; few discontinuations due to treatment emergent adverse events (TEAEs)Read More | Lexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Swain Judith LDirector | Option | 89,312 174,486 held | $0.00 | 06/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LXRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 395.22 K | 164.67 K |
LXRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LXRX ranks across every disease it competes in
Competitive Position is a premium feature
See how LXRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLXRX News
LXRXLexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Lexicon Pharmaceuticals has announced its participation in three upcoming investor conferences in New York. The conferences include the Citi 2026 Biopharma Back to School Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. These events will provide opportunities for the company to showcase its pipeline and engage with investors.
Read more →LXRXLexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Lexicon Pharmaceuticals announced positive results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial. The analysis showed that sotagliflozin is effective across different baseline blood pressure levels in patients with recent worsening heart failure. These findings were presented at the ESC Congress 2026 and published in JACC: Heart Failure.
Read more →LXRXLexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Lexicon Pharmaceuticals announced the receipt of a third $10 million milestone payment from Novo Nordisk, following the achievement of a key patient dosing milestone for LX9851 in Phase 1 clinical development. The collaboration could yield up to $1 billion in total payments for Lexicon. The Phase 1 program, initiated in March 2026, aims to evaluate the safety and efficacy of LX9851 for obesity treatment.
Read more →LXRXLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals reported its financial results for Q2 2026, highlighting the completion of enrollment in the Phase 3 SONATA-HCM study and nearing completion of NDA resubmission for ZYNQUISTA in type 1 diabetes. The company anticipates top-line data from the SONATA-HCM study in Q1 2027. Despite a net loss of $31.8 million, Lexicon's cash and investments increased significantly, reflecting ongoing strategic efforts.
Read more →LXRXLexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Lexicon Pharmaceuticals will release its second quarter 2026 financial results on August 6, 2026, before market opening. A conference call and live webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update. Interested participants can access the call via the company's website.
Read more →LXRXLexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Lexicon Pharmaceuticals has completed patient enrollment for the pivotal Phase 3 SONATA-HCM study evaluating sotagliflozin in hypertrophic cardiomyopathy. The trial exceeded its target of 500 patients across 130 sites in 20 countries. Topline results are expected in Q1 2027, with the study focusing on symptomatic improvement in both non-obstructive and obstructive HCM patients.
Read more →LXRXLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Lexicon Pharmaceuticals will present data on sotagliflozin and pilavapadin at the ADA 2026 Scientific Sessions. The presentations will focus on the efficacy of sotagliflozin in Type 1 diabetes and the pharmacokinetics of pilavapadin. The company is optimistic about the potential resubmission of an NDA for sotagliflozin in mid-2026.
Read more →LXRXLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The event will take place in New York City at 2:00 p.m. ET. Attendees can access the live event and replay via the company's website. Lexicon focuses on developing innovative medicines for various medical conditions.
Read more →LXRXLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026. The event will be held at the Nasdaq World Headquarters in New York City. Interested parties can access the live event and its replay through the company's website.
Read more →LXRXLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals reported its Q1 2026 financial results, highlighting a strong financial position bolstered by a recent capital raise and a $100 million loan facility. Key clinical updates include the anticipated NDA resubmission for ZYNQUISTA in type 1 diabetes and ongoing enrollment in the SONATA-HCM trial. The company aims to achieve several pivotal milestones in the coming year.
Read more →LXRXLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals has announced a $100 million loan facility with Hercules Capital, providing significant financial flexibility. The initial $55 million will refinance existing debt, while additional funds will support clinical and regulatory milestones. This partnership aims to bolster Lexicon's pipeline in cardiometabolic programs and reflects a strategic move towards operational excellence.
Read more →LXRXLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Lexicon Pharmaceuticals will announce its first quarter 2026 financial results on May 7, 2026, before the market opens. A conference call and live webcast will follow at 8:30 a.m. ET to discuss the results and provide a business update. The company is focused on developing transformative medicines across several therapeutic areas.
Read more →LXRXLexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Lexicon Pharmaceuticals announced that it will present data from its PROGRESS Phase 2b study of pilavapadin at the AAN Annual Meeting. The study supports the selection of 10 mg as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). Additionally, data on spasticity endpoints will be presented, highlighting the broader potential of the AAK1 pathway in neurologic diseases.
Read more →LXRXLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Lexicon Pharmaceuticals announced three presentations of sotagliflozin clinical data at the ACC Annual Meeting. The data from the Phase 3 SCORED study indicated that sotagliflozin effectively reduced heart failure and major adverse cardiovascular events, regardless of BMI. Additional analyses from the SOTA-P-CARDIA trial showed improvements in quality of life for non-diabetic patients with heart failure.
Read more →LXRX▲ +5.1%on this newsshared move
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Lexicon Pharmaceuticals and Novo Nordisk have announced the initiation of a Phase 1 study for LX9851, an oral candidate aimed at treating obesity and metabolic disorders. Lexicon has secured a second milestone payment of $10 million and stands to earn up to $1 billion in total payments from the collaboration. The study will assess the safety and efficacy of LX9851 in 96 participants, with completion expected by Q1 2027.
Read more →LXRXLexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Read more →LXRXLexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals reported its financial results for Q4 2025, highlighting significant progress in its clinical pipeline, including the advancement of pilavapadin into Phase 3 and ongoing enrollment in the SONATA study for HCM. The company secured over $100 million in funding, bolstering its financial position. Despite a net loss, Lexicon remains optimistic about its future prospects and upcoming milestones.
Read more →LXRXLexicon Pharmaceuticals to Participate in Three Upcoming March 2026 Investor Conferences
Lexicon Pharmaceuticals announced its participation in three investor conferences in March 2026. The company will engage in a fireside chat at the Leerink Partners Global Healthcare Conference and hold 1x1 meetings at the Jefferies Biotech on the Beach Summit and Barclays Global Healthcare Conference. This involvement highlights Lexicon's commitment to investor relations and showcases its ongoing development efforts.
Read more →LXRXLexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Lexicon Pharmaceuticals announced it will release its fourth quarter 2025 financial results on March 5, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Participants can access the call via webcast and will have the opportunity to ask questions.
Read more →LXRXLexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Lexicon Pharmaceuticals has announced the successful closing of a public offering, raising approximately $94.6 million through the sale of 32 million shares of common stock and a concurrent private placement. The proceeds will be utilized for research and development of drug candidates and general corporate purposes. The company granted underwriters an option to purchase additional shares, enhancing potential funding.
Read more →About Lexicon Pharmaceuticals, Inc.
Headquarters2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381
BIOPHARMAWATCH ELITE PLUS
Trade the next LXRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime